Royalty Report: Drugs, Disease, Therapeutic – Collection: 6903

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Cancer
  • Biotechnology
  • Pharmaceuticals
  • Pain
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4251

License Grant
Licensor hereby grants to Licensee of Bermuda during the Term an exclusive, sublicenseable license or sublicense, as applicable, under the Infinity Know-How, Infinity Patent Rights and Product Trademarks to Commercialize Products in the applicable Territory.
License Property
Alliance Product shall mean (a) products and product candidates that Interact with the Hedgehog Pathway, (b) products and product candidates that Interact with FAAH, and (c) products and product candidates that arise out of the Discovery Projects and either (x) have been separately identified in the Research Plan submitted by Infinity to Licensee as of October 1 immediately prior to the end of the Funded Discovery Period, or (y) have achieved Development Candidate status on or before the end of the Funded Discovery Period; provided, however, that, Alliance Products will not include (i) products and product candidates that Interact with Hsp90 or Bcl-2/Bcl-xL, (ii) any products and product candidates that Infinity in-licenses or otherwise acquires rights to from a Third Party after the Effective Date, and (iii) any Opt-Out Products, Assumed Products or Related Products associated therewith.

FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.

Hedgehog Pathway shall mean all of the following members of the Hedgehog cell-signaling pathway: (i) all hedgehog ligands (Sonic, Indian, Desert) and transmembrane transport-like proteins, like Disp1 or Disp2, involved in the secretion of the HH ligand, (ii) Smoothened (Smo), including alternatively spliced forms and Smo with activating mutations, (iii) all Gli transcription factors (Gli 1, 2, 3), (iv) mutated or unmutated Patched (Ptch) receptor 1 and 2, (v) Cdo, Cdon and Boc (brother of Cdo), (vi) Suppressor of Fused (SuFu), (vii) Cdc2l1 kinase, (viii) Hedgehog interacting protein (HHIP), and (ix) ARL13B.

Field of Use
The Parties are interested in forming an alliance whose goal is to (a) enable Infinity to build a portfolio of oncology products and a commercial oncology organization in the United States and (b) provide Licensee with a pipeline of products to commercialize outside of the United States.

IPSCIO Record ID: 6903

License Grant
Licensor of Bermuda hereby grants to Licensee during the Term an exclusive, sublicenseable license or sublicense, as applicable, under the Infinity Know-How, Infinity Patent Rights and Product Trademarks to Commercialize Products in the applicable Territory.
License Property
Alliance Product shall mean (a) products and product candidates that Interact with the Hedgehog Pathway, (b) products and product candidates that Interact with FAAH, and (c) products and product candidates that arise out of the Discovery Projects and either (x) have been separately identified in the Research Plan submitted by Infinity to MICL as of October 1 immediately prior to the end of the Funded Discovery Period, or (y) have achieved Development Candidate status on or before the end of the Funded Discovery Period; provided, however, that, Alliance Products will not include (i) products and product candidates that Interact with Hsp90 or Bcl-2/Bcl-xL, (ii) any products and product candidates that Infinity in-licenses or otherwise acquires rights to from a Third Party after the Effective Date, and (iii) any Opt-Out Products, Assumed Products or Related Products associated therewith.

FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.

Hedgehog Pathway shall mean all of the following members of the Hedgehog cell-signaling pathway: (i) all hedgehog ligands (Sonic, Indian, Desert) and transmembrane transport-like proteins, like Disp1 or Disp2, involved in the secretion of the HH ligand, (ii) Smoothened (Smo), including alternatively spliced forms and Smo with activating mutations, (iii) all Gli transcription factors (Gli 1, 2, 3), (iv) mutated or unmutated Patched (Ptch) receptor 1 and 2, (v) Cdo, Cdon and Boc (brother of Cdo), (vi) Suppressor of Fused (SuFu), (vii) Cdc2l1 kinase, (viii) Hedgehog interacting protein (HHIP), and (ix) ARL13B.

Field of Use
Licensee and Licensor are interested in forming an alliance whose goal is to (a) enable Infinity to build a portfolio of oncology products and a commercial oncology organization in the United States and (b) provide Licensor with a pipeline of products to commercialize outside of the United States.

IPSCIO Record ID: 4255

License Grant
Licensor hereby grants to Licensee during the Term an exclusive, sublicenseable license or sublicense, as applicable, under the Infinity Know-How and Infinity Patent Rights to Commercialize FAAH Products in the Territory.
License Property
FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.

An innovative drug discovery and development company, today announced that it has commenced clinical development of its fourth internally discovered drug candidate, IPI-940, a novel inhibitor of the enzyme fatty acid amide hydrolase, or FAAH. After Phase 1 investigation, two Licensees will have the right to assume worldwide development and commercialization activities under the Licensor's FAAH program.

Field of Use
IPI-940, a potential treatment for a broad range of neuropathic and inflammatory pain conditions, is a selective, orally available inhibitor of FAAH. Inhibitors of FAAH have the ability to potentiate the magnitude and duration of the body’s endogenous analgesic agents through their effects on the endocannabinoid system. After Phase 1 investigation, the Licensees will have the right to assume worldwide development and commercialization activities under the FAAH program.

IPSCIO Record ID: 6588

License Grant
Licensor hereby grants to Licensee an exclusive, with right to sublicense, license or sublicense, as applicable, under the Infinity Know-How and Infinity Patent Rights to Commercialize FAAH Products in the Territory.
License Property
FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.

The Parties are interested in forming an alliance whose goal is to develop and commercialize FAAH Products in the United States.

The Company has commenced clinical development of its internally discovered drug candidate, IPI-940, a novel inhibitor of the enzyme fatty acid amide hydrolase, or FAAH. After Phase 1 investigation, select Licensees will have the right to assume worldwide development and commercialization activities under the Licensor's FAAH program.

IPI-940, a potential treatment for a broad range of neuropathic and inflammatory pain conditions, is a selective, orally available inhibitor of FAAH. Inhibitors of FAAH have the ability to potentiate the magnitude and duration of the body’s endogenous analgesic agents through their effects on the endocannabinoid system. After Phase 1 investigation, the Licensees will have the right to assume worldwide development and commercialization activities under the FAAH program.

IPSCIO Record ID: 4330

License Grant
The Licensor, on behalf of itself and its Affiliates, grants to the Licensee during the Term an exclusive, sublicenseable, irrevocable license or sublicense, as applicable, under the Know-How and Patent Rights to Develop, Manufacture and Commercialize FAAH Products anywhere in the world.
License Property
The Licensor transfers and assigns to the Licensee all right, title and interest in and to any product name or related trademark that had been selected by the Licensor or its Affiliates with respect to the FAAH Products and any Internet domain names incorporating any Product Trademark or any variation or part of any such Product Trademark as its URL address.

FAAH shall mean Fatty Acid Amide Hydrolase

Fatty acid amide hydrolase, (FAAH, Oleamide hydrolase, Anandamide amidohydrolase), is an integral membrane protein that hydrolyzes bioactive amides, including anandamide, to free fatty acid and ethanolamine. In humans, FAAH is mainly present in the pancreas, brain, kidney, skeletal muscle, and placenta.

IPSCIO Record ID: 249348

License Grant
Licensor grants a sublicensable right and license under Collaboration Rights and Licensor General Rights that is co-exclusive with Licensor to make and have made such Product in any country of the world for sale in such countries, and use, sell, offer to sell and import such Products in such countries in the Field, in accordance with the terms and conditions of this Agreement, and such license shall automatically terminate for a Project, and for each Product in the Project, as to which Licensee becomes an Opt-Out Party effective as of the Opt-Out Date.
License Property
Product means an Hsp90 Product and/or Hedgehog Product.  Project means Hedgehog Project and/or Hsp90 Project.

Hsp90 Diagnostic means a product or service for determining a person that is susceptible to treatment with a Hsp90 Therapeutic and/or monitoring such treatment and/or providing a prognosis of such treatment, in each case such treatment being for the purpose of treating and/or preventing a disease, disorder or condition.

Hsp90 Therapeutic means one or more molecules that primarily (i.e. the most potent activity) target and modulate one or more of Heat Shock Protein 90 (Hsp90) [and/or cochaperones of Heat Shock Protein 90 ( e.g. Hip and Hop), but not client proteins of Heat Shock Protein 90 such as c-Kit and EGFR,] and compositions that contain such a molecule(s). For the avoidance of doubt, the chemical entities disclosed and/or claimed in the Patent Rights indicated in Exhibit Y and IPI 504 are included as Hsp90 Therapeutics.

Hedgehog Diagnostic means a product or service for determining a person that is susceptible to treatment with a Hedgehog Therapeutic and/or monitoring such treatment and/or providing a prognosis of such treatment, in each case such treatment being for the purpose of treating and/or preventing a disease, disorder or condition.

Hedgehog Therapeutic means one or more molecules that primarily target (i.e. the most potent activity) and modulate one or more member(s) of the Hedgehog pathway and compositions that contain such a molecule(s). For the avoidance of doubt, the chemical entities disclosed and/or claimed in the Patent Rights [, and IPI 609, the IPI 609 polymorph, and reduced A-ring analogs of IPI 609] are included as Hedgehog Therapeutics.

The Licensee Patents are for Analogs ofBenzoquinone-Containing Ansamycins and Methods of Use Thereof, and,  Ansamycin Formulations and Methods of use Thereof, and,  Methods of Treatment Using Hydroquinone Ansamycins, and,  Crystal Form, and, Cyclopamine Analogs and Methods of Use Thereof , and, Dosing Regimens for the Treatment of Cancer, and,  Methods for Synthesizing Cyclopamine Analogs.

Field of Use
The collaborative agreement is to jointly develop and commercialize novel small molecule cancer drugs targeting Heat Shock Protein 90 (“Hsp90”) and the Hedgehog cell-signaling pathway.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.